Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Leukemia|January 19, 2026
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath resultsDelphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, et al.
Cell Death & Disease|September 26, 2021
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cellsAlena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
Leukemia Research|January 18, 2003
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemiaAstrid Gruber, Magnus Björkholm, Lorentz Brinch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib TherapyNoortje Thielen, Johan Richter, Matthias Baldauf, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Journal of Cancer Research and Clinical Oncology|March 25, 2017
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemiaHanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, et al.
Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.
European Journal of Haematology|August 21, 2021
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 studyHjalmar Flygt, Stina Söderlund, Jesper Stentoft, et al.
Blood|July 12, 2013
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registryMartin Höglund, Fredrik Sandin, Karin Hellström, et al.
Pageof 8